OX40 Controls Functionally Different T Cell Subsets and Their Resistance to Depletion Therapy
Overview
Authors
Affiliations
T cell depletion is a widely used approach in clinical transplantation. However, not all T cells are equally sensitive to depletion therapies and a significant fraction of T cells persists even after aggressive treatment. The functional attributes of such T cells and the mechanisms responsible for their resistance to depletion are poorly studied. In the present study, we showed that CD4(+) T cells that are resistant to polyclonal anti-lymphocyte serum (ALS) mediated depletion exhibit phenotypic features of memory cells and uniformly express OX40 on the cell surface. Studies using the foxp3gfp knockin mice revealed that the remaining CD4(+)OX40(+) cells consist of Foxp3(+) Tregs and Foxp3(-) T effector/memory cells. The ALS-resistant CD4(+)OX40(+) cells failed to mediate skin allograft rejection upon adoptive transferring into congenic Rag(-/-) mice, but removal of Foxp3(+) Tregs from the OX40(+) cells resulted in prompt skin allograft rejection. Importantly, OX40 is critical to survival of both Foxp3(+) Tregs and T effector/memory cells. However, OX40 exhibits opposing effects on the functional status of Foxp3(+) Tregs and T effector/memory cells, as stimulation of OX40 on T effector cells induced amplified cell proliferation but stimulation of OX40 on the Foxp3(+) Tregs impaired their suppressor functions. Our study demonstrates that OX40 is a critical molecule in regulating survival and functions of depletion-resistant T cells; and these findings may have important clinical implications.
Regulatory T cells in lung disease and transplantation.
Lao P, Chen J, Tang L, Zhang J, Chen Y, Fang Y Biosci Rep. 2023; 43(10).
PMID: 37795866 PMC: 10611924. DOI: 10.1042/BSR20231331.
Crespo E, Vidal-Alabro A, Jouve T, Fontova P, Stein M, Mocka S Front Immunol. 2022; 13:869554.
PMID: 35833145 PMC: 9272702. DOI: 10.3389/fimmu.2022.869554.
Ma H, Feng P, Yu S, Lu Z, Yu Q, Chen J BMC Cancer. 2022; 22(1):543.
PMID: 35562682 PMC: 9107201. DOI: 10.1186/s12885-022-09654-6.
Jin F, Liu D, Xu X, Ji J, Du Y Int J Nanomedicine. 2021; 16:4693-4712.
PMID: 34267518 PMC: 8275223. DOI: 10.2147/IJN.S314506.
Emerging Targets of Immunotherapy in Gynecologic Cancer.
Cheng H, Zong L, Kong Y, Gu Y, Yang J, Xiang Y Onco Targets Ther. 2020; 13:11869-11882.
PMID: 33239889 PMC: 7681579. DOI: 10.2147/OTT.S282530.